TGTX - TG Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5569.48M
Enterprise Value 3482.62M
Trailing P/E N/A
Forward P/E 1-4.70
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)3,746.57
Price/Book (mrq)39.54
Enterprise Value/Revenue 33,175.10
Enterprise Value/EBITDA 6-3.04

Trading Information

Stock Price History

Beta (3Y Monthly) 2.16
52-Week Change 3-49.88%
S&P500 52-Week Change 30.90%
52 Week High 312.90
52 Week Low 33.32
50-Day Moving Average 37.29
200-Day Moving Average 37.12

Share Statistics

Avg Vol (3 month) 31.34M
Avg Vol (10 day) 31.1M
Shares Outstanding 590.84M
Float 59.35M
% Held by Insiders 111.16%
% Held by Institutions 168.87%
Shares Short (Jul 31, 2019) 413.35M
Short Ratio (Jul 31, 2019) 411.29
Short % of Float (Jul 31, 2019) 420.51%
Short % of Shares Outstanding (Jul 31, 2019) 414.69%
Shares Short (prior month Jun 28, 2019) 414.43M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 25625/100
Last Split Date 3Apr 30, 2012

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-104,414.48%

Management Effectiveness

Return on Assets (ttm)-80.22%
Return on Equity (ttm)-277.85%

Income Statement

Revenue (ttm)152k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)0.00%
Gross Profit (ttm)152k
EBITDA -158.62M
Net Income Avi to Common (ttm)-159.18M
Diluted EPS (ttm)-1.96
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)84.98M
Total Cash Per Share (mrq)0.96
Total Debt (mrq)38M
Total Debt/Equity (mrq)287.79
Current Ratio (mrq)1.69
Book Value Per Share (mrq)0.15

Cash Flow Statement

Operating Cash Flow (ttm)-135.91M
Levered Free Cash Flow (ttm)-76.58M